Iniciar sesión Regístrese gratis

Last updated: 31 January 2023 at 2:30pm EST

Catherine Sazdanoff Net Worth




The estimated Net Worth of Catherine Sazdanoff is at least $365 mil dollars as of 29 April 2016. Ms. Sazdanoff owns over 7,700 units of Meridian Bioscience stock worth over $261,569 and over the last 9 years she sold VIVO stock worth over $0. In addition, she makes $103,333 as Independent Director at Meridian Bioscience.

Ms. Sazdanoff VIVO stock SEC Form 4 insiders trading

Catherine has made over 1 trades of the Meridian Bioscience stock since 2016, according to the Form 4 filled with the SEC. Most recently she bought 7,700 units of VIVO stock worth $147,840 on 29 April 2016.

The largest trade she's ever made was buying 7,700 units of Meridian Bioscience stock on 29 April 2016 worth over $147,840. On average, Catherine trades about 592 units every 0 days since 2015. As of 29 April 2016 she still owns at least 7,700 units of Meridian Bioscience stock.

You can see the complete history of Ms. Sazdanoff stock trades at the bottom of the page.





Catherine Sazdanoff biography

Catherine Ann Sazdanoff J.D. serves as Independent Director of the Company. Catherine A. Sazdanoff is the President and Chief Executive Officer of Sazdanoff Consulting, LLC, providing health care strategy and business development advisory services to a number of clients, since January 2015. She also currently serves as Business Advisor to Strata Oncology, Inc., a precision oncology company, having joined Strata in May 2016 as Chief Business Officer (May 2016 – September 2017). Since July 2019, Ms. Sazdanoff has served as an independent director of the Board of InMed Pharmaceuticals, Inc., currently chairing its nominating and governance committee. Ms. Sazdanoff is also a member since April 2016 of the Advisory Board of Neurocern, Inc., a dementia insuretech company, and is a lecturer since March 2018 in the Business of Biotech program at the University of Chicago Graham School for Continuing and Professional Education. She serves on the External Advisory Board of the Rosalind Franklin University Innovation and Research Park. Ms. Sazdanoff’s prior corporate roles include a number of global corporate positions with Takeda Pharmaceuticals, Inc. (“Takeda”), a wholly-owned subsidiary of Japanese-based Takeda Pharmaceutical Corporation, from 2006 to 2015 including VP, Head of Corporate Projects (2012-2015), VP, Global Business Development (2011-2013) and VP, Corporate Development (2010-2011). Ms. Sazdanoff’s time at Takeda was preceded by approximately 22 years with Abbott Laboratories, where she held numerous executive positions covering legal, compliance and business development. The Board believes that Ms. Sazdanoff’s years of experience in the pharmaceutical and medical diagnostics industries makes her service on the Board valuable to Meridian.

What is the salary of Catherine Sazdanoff?

As the Independent Director of Meridian Bioscience, the total compensation of Catherine Sazdanoff at Meridian Bioscience is $103,333. There are 10 executives at Meridian Bioscience getting paid more, with John P. Kenny having the highest compensation of $1,508,705.



How old is Catherine Sazdanoff?

Catherine Sazdanoff is 63, she's been the Independent Director of Meridian Bioscience since 2015. There are 4 older and 9 younger executives at Meridian Bioscience. The oldest executive at Meridian Bioscience Inc. is David Phillips, 81, who is the Independent Chairman of the Board.

What's Catherine Sazdanoff's mailing address?

Catherine's mailing address filed with the SEC is 3471 RIVER HILLS DRIVE, , CINCINNATI, OH, 45244.

Insiders trading at Meridian Bioscience

Over the last 22 years, insiders at Meridian Bioscience have traded over $8,089,514 worth of Meridian Bioscience stock and bought 228,244 units worth $3,053,655 . The most active insiders traders include Richard Eberly, John P. Kenny y John A Kraeutler. On average, Meridian Bioscience executives and independent directors trade stock every 41 days with the average trade being worth of $424,761. The most recent stock trade was executed by James M. Anderson on 6 January 2023, trading 8,500 units of VIVO stock currently worth $173,230.



What does Meridian Bioscience do?

Meridian Bioscience Inc. is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.The company is dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, Meridian provides critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, Meridian provides diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. The company builds relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.



What does Meridian Bioscience's logo look like?

Meridian Bioscience Inc. logo

Complete history of Ms. Sazdanoff stock trades at Meridian Bioscience y InMed Pharmaceuticals

Fecha
#
Empresa
 Persona
Trans.
Transacción
 Acciones Precio por acción Precio total Acciones después de Fuente
29 Apr 2016 VIVO Meridian Bioscience Inc. Catherine Sazdanoff
Director
 Comprar 7,700 $19.20 $147,840
29 Apr 2016
7,700 ↗


Meridian Bioscience executives and stock owners

Meridian Bioscience executives and other stock owners filed with the SEC include: